 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
My stock research is NOT being sent out as a buy or sell advisement but just for your review and consideration. I do own stock in this one obviously. Ticker Fundamental Data: dbc.com Location: Wasatch Pharmaceutical, Inc., 714 East 7200 South, Midvale, UT 84047 Contact: David Giles, CFO, (801) 566-9688 or Todd Hickman (281) 370-2544 Description of Business: Operates two medical skin care clinics using new breakthrough technology for the treatment of common skin disorders including acne, ecaema, psoriasis. Shares Issued: approx. 10,261,956 Insider: approx. 3,922,565 Total Restricted Shares: 9,084,737 Free Trading Float: 601,719 Transfer Agent: Standard Registar / (801) 571-8844 / Ron Harrington Recent News: biz.yahoo.com Marketers: investmentcapital.com Sec Filing:http://sec.yahoo.com/e/l/w/wasp.html Profile: investmentcapital.com Chart: dbc.com Company Notes: Wasatch Pharmaceutical has been in business fourteen years as a research entity in the field of dermatology. The products and medical therapies developed by this company represent the most important breakthroughs in the field of dermatology in the last fifteen years. The example that best describes their success in the treatment of serious skin diseases is represented in a typical dermatology clinic treating one hundred patients at any given time. Seventy of those patients cannot be treated successfully by the physician. In contrast, those same seventy patients can be treated successfully by therapies developed by Wasatch Pharmaceutical. Success is interpreted as eradication of these skin diseases in excess of 90% of all skin diseases with the exception of psoriasis which has a 70% success rate. In light of these successes, Wasatch Pharmaceutical is without question in a position to maintain a leadership role in dermatology; and intends to do so through the establishment of three hundred company owned clinics over the next five years. Additional marketing efforts will be in the training of established dermatologists throughout the US to come on line with the use of Wasatch products in their medical practice. In the past Wasatch has elected to remain a quiet company with no appetite for public disclosures. Having recently become a public company this attitude has changed, they are now ready to take the wraps off their accomplishments in order to take the level of marketing their technologies throughout the US and eventually into foreign markets. All products are full FDA compliant and several patents have been applied for. BARD Notes: The company note explains it all. They are about to embark on the next level of marketing which is the products they have developed. Please READ everything and I think you will see why I am sending this one out. Remember: Trade what is comfortable for you, not on what others say or do. This is my opinion and NEVER trade based on some one else's opinion. Thanks, GaBard | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |